Legal Representation
Attorney
Erik Eglite
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 25, 2023 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Jul 31, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 31, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 9, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 7, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 7, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 7, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 28, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 3, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 3, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 13, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 31, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 31, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 31, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 31, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 31, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 28, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 28, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 28, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 13, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 3, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005